Sales & Marketing News | pharmaphorum

News

China's clears Pfizer GLP-1 ecnoglutide for weight loss

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for Sciwind-sourced ecnoglutide.

News

J&J's Tecvayli claims third national priority FDA approval

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

Lilly unveils employer scheme for weight-loss drug Zepbound

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

Hansa closes on FDA verdict for transplant drug imlifidase

The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.

News

Moderna agrees $950m settlement of mRNA jab litigation

Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

China's clears Pfizer GLP-1 ecnoglutide for weight loss

J&J's Tecvayli claims third national priority FDA approval

Lilly unveils employer scheme for weight-loss drug Zepbound

Hansa closes on FDA verdict for transplant drug imlifidase

Moderna agrees $950m settlement of mRNA jab litigation

FDA ramps up its pushback against compounded GLP-1s

FDA issues warning letters to five unapproved GLP-1 websites

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks